Business Wire

Ares Management Prices First European Direct Lending CLO at£305 Million

Share

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its first European Direct Lending Collateralized Loan Obligation (“CLO”), Ares European Direct Lending CLO 1, at £305 million. Ares believes this is the first reinvesting CLO in the European Direct Lending market and is one of the first direct lending CLOs issued in Europe.

Ares European Direct Lending CLO 1 is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 50 middle-market companies based in the United Kingdom, primarily operating in defensive industries. The CLO, which is weighted towards senior-secured floating rate loans, will be rated by S&P and KBRA.

“This successful pricing of our first European Direct Lending CLO is a testament to Ares’ 18 years of leadership in European private credit and builds on our ability to source, underwrite and manage scaled portfolios of direct loans,” said Michael Dennis, Partner and Co-Head of European Credit. “We are grateful for the strong support we have received in our efforts to deliver a differentiated product suite to meet the growing demand from investors and borrowers.”

“We believe the strong demand for this product underscores our new and existing investors’ confidence in our platform’s experience in quality credit selection and managing direct loans and bespoke structures,” said Andrea Fernandez, Partner & Head of Product Management and Investor Relations for European Credit.

“In navigating a complex and volatile market environment, we will continue to harness our investment discipline and portfolio management capabilities as we seek to generate risk-adjusted returns for our investors,” said Matt Theodorakis, Partner and Co-Head of European Direct Lending.

Ares’ European Direct Lending strategy comprises approximately 95 investment professionals operating across seven offices in Europe and manages over $77 billion in assets as of March 31, 2025. Since its inception in 2007, the European Direct Lending business has completed over 390 investments totaling over €73 billion. In addition to this, Ares is one of the largest and most experienced CLO managers globally, having issued 107 CLOs since 1999, of which 60 are active today. As of March 31, 2025, Ares’ CLO portfolio represented $32 billion of the $359 billion of assets managed across the Ares Credit Group.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation's global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.aresmgmt.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250608608618/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 15:04:00 CEST | Press release

New platform unifies agents, models, knowledge, and data to finally deliver on the promise of AI as a transformative force for business Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. I

Capcom’s Resident Evil Requiem, the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 15:00:00 CEST | Press release

– The highly anticipated new installment to launch during the series’ 30th anniversary – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders9.6.2025 14:40:00 CEST | Press release

PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. This press release features multimedia. View the ful

Tier-1 MVNO Selects Tecnotree’s AI-Native BSS for Multi-Country Transformation Across UK & Europe9.6.2025 14:36:00 CEST | Press release

Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609328949/en/ This engagement will see the full-stack replacement of the MVNO’s legacy systems with Tecnotree’s composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent. The deploy

Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic9.6.2025 14:00:00 CEST | Press release

Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609975546/en/ Glenn Crater, MD, FCCP, appointed Chief Medical Officer of Innospera Pharma Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Inno

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye